Estimated longevity benefit: +1.5 years. Evidence score: 97/100.
Metformin is a biguanide pharmaceutical that activates AMPK and mimics the cellular effects of caloric restriction. While traditionally used for type 2 diabetes, observational data suggests it may extend lifespan by reducing systemic inflammation and improving metabolic efficiency in non-diabetic populations.
Metformin is the subject of the landmark TAME (Targeting Aging with Metformin) trial - the first FDA-approved study using aging itself as an endpoint. Interest stems from observational studies showing diabetics on metformin lived longer than non-diabetic controls - an unexpected finding given diabetes typically shortens lifespan. Proposed mechanisms include AMPK activation (mimicking caloric restriction), reduced mTOR signaling, decreased inflammation, and improved mitochondrial function. By activating AMPK, metformin shifts the cell into a preservation mode, enhancing autophagy and reducing oxidative stress. A UK Prospective Diabetes Study found metformin reduced all-cause mortality by 36% compared to other diabetes treatments. However, recent studies suggest metformin may blunt exercise adaptations by 30-50%, particularly in older adults. This interaction suggests that the drug may interfere with the beneficial reactive oxygen species generated during intense physical activity. The TAME trial will clarify whether benefits extend to non-diabetics, but results aren't expected until late 2020s.
Important Note: Metformin is a potent pharmaceutical agent that requires professional medical oversight to manage its systemic effects and potential interactions. Understanding the current regulatory status and the ongoing research landscape is crucial for anyone considering its off-label use for longevity. - This is a prescription medication - cannot be obtained over the counter - Requires physician supervision and regular blood work monitoring - Currently off-label for longevity (FDA-approved only for type 2 diabetes) - Discuss with a doctor familiar with longevity medicine; many concierge and longevity-focused practices prescribe it - The TAME (Targeting Aging with Metformin) trial will provide definitive human longevity data, but results are not expected until the late 2020s
Getting Started: The initial phase involves establishing a medical partnership and obtaining a clear picture of your baseline metabolic health. Because metformin is cleared by the kidneys and can affect B12 levels, specific baseline metrics are mandatory before the first dose. - Find a physician willing to prescribe off-label (longevity medicine doctors, functional medicine practitioners, or progressive primary care physicians) - Baseline blood work before starting: fasting glucose, HbA1c, comprehensive metabolic panel (kidney and liver function), B12 levels, CBC - Request extended-release (ER) formulation from the outset - significantly fewer GI side effects than immediate-release - Metformin is inexpensive ($4-15/month for generic) and widely available
Titration Schedule (Go Slow): Gastrointestinal distress is the most common reason for discontinuing metformin, but it can almost always be managed through a very gradual increase in dosage. This titration allows your gut microbiome and digestive system to adapt to the drug's presence without overwhelming symptoms. - Week 1-2: 250mg with dinner (or 500mg ER with dinner) - Week 3-4: 500mg with dinner (or 500mg ER twice daily) - Week 5-6: Increase to 750mg if tolerated - Week 7+: Reach target dose of 1000mg daily if tolerated (some use up to 1500mg) - If GI side effects occur at any stage, hold at the current dose for an extra 2 weeks before increasing - GI side effects (nausea, diarrhea, bloating) usually resolve within 2-4 weeks at each dose level
Optimal Dosing for Longevity: Longevity-focused dosing is typically lower than the doses used for managing active diabetes, aiming for metabolic optimization rather than aggressive glucose lowering. Using the extended-release version at dinner aligns the drug's peak effect with your largest meal and overnight metabolic processes. - Most longevity practitioners recommend 500-1000mg daily (lower than diabetic dosing of 1500-2000mg) - Take with dinner or the largest meal to reduce GI side effects and align with blood sugar management - Extended-release (ER) formulation is strongly preferred - better tolerated and more consistent drug levels - Some practitioners use 500mg once daily as a maintenance longevity dose - Higher doses (1500mg+) increase side effects without clearly proportional longevity benefit in non-diabetics
Managing Side Effects: While often temporary, gastrointestinal side effects can be significant and require active management strategies to overcome. Most issues can be resolved by adjusting timing, ensuring the drug is taken with a full meal, or switching to the extended-release formulation. - Nausea/diarrhea: Most common (20-30% of users initially), usually temporary - resolves in 2-4 weeks - Switch to extended-release if immediate-release causes persistent GI issues - Always take with food, never on an empty stomach - Reduce dose temporarily if symptoms are severe; try again in 1-2 weeks - Metallic taste: Reported by some users; usually diminishes over time - If GI issues persist beyond 6 weeks on ER formulation, the medication may not be right for you
Critical Supplement - Vitamin B12: Long-term metformin use is clinically proven to impair the absorption of Vitamin B12, which can lead to neurological damage if not addressed. Proactive supplementation and annual testing are essential components of any metformin-based longevity protocol. - Metformin impairs B12 absorption by 10-30% - this is cumulative over years - Supplement with methylcobalamin (active form) 1000-2000mcg daily - Test B12 and methylmalonic acid (MMA) levels at baseline and annually - Take B12 at a different time than metformin (morning if metformin is taken at dinner) - B12 deficiency causes irreversible nerve damage if left unchecked - do not skip this
Monitoring Schedule: Regular laboratory testing ensures that the medication is having the intended metabolic effect while confirming that kidney and liver function remain within healthy parameters. This objective data allows for precise dose adjustments and early identification of any rare adverse reactions. - Baseline: Fasting glucose, HbA1c, comprehensive metabolic panel, B12, CBC, lactate - 3 months: Repeat fasting glucose and HbA1c to confirm metabolic effect - 6 months: Comprehensive metabolic panel, B12 levels - Annually thereafter: Full panel including kidney function (eGFR, creatinine), B12, HbA1c, liver enzymes - Watch for signs of lactic acidosis (extremely rare but serious): unusual muscle pain, difficulty breathing, stomach pain, dizziness
Exercise Consideration (Important Trade-Off): The potential for metformin to blunt the beneficial adaptations to exercise represents a significant strategic choice for longevity-seekers. Many practitioners now advocate for "pulsed" dosing to allow for maximum training adaptations while still gaining the metabolic benefits of the drug. - Research suggests metformin may blunt muscle and cardio adaptations by 30-50%, particularly in older adults - The mechanism: Metformin activates AMPK (which competes with mTOR, the muscle-building pathway), and may reduce mitochondrial reactive oxygen species needed for exercise adaptation signaling - Some practitioners skip metformin on heavy training days (skip the dose before and after intense workouts) - Others take metformin only on rest days or use 4-5 days on, 2-3 days off (around training) - This is an active area of research - the evidence is not yet definitive - Weigh the exercise blunting against metformin's other potential benefits based on your priorities
Timeline of Expected Effects: The benefits of metformin accumulate over months and years rather than days, starting with subtle shifts in blood sugar and inflammatory markers. Understanding this timeline helps set realistic expectations and emphasizes the importance of long-term consistency. - Weeks 1-4: GI adjustment period; fasting glucose may begin to decline - Months 1-3: HbA1c and fasting insulin typically improve; AMPK activation is occurring at the cellular level - Months 3-6: Inflammatory markers (hs-CRP) may decrease; metabolic improvements stabilize - Months 6-12: Full metabolic benefits should be apparent on blood work - Years 1+: Theoretical anti-aging effects (reduced cancer risk, improved autophagy) - these are the benefits being tested in TAME trial
Common Mistakes: Most failures with metformin come from poor implementation rather than drug failure, particularly starting at too high a dose or neglecting secondary nutrient needs. Awareness of these common errors can significantly improve your success and safety with the intervention. - Starting at too high a dose and experiencing severe GI side effects that discourage continued use - Not supplementing B12 from the beginning - Using immediate-release instead of extended-release formulation - Not monitoring kidney function (metformin is cleared by the kidneys) - Combining with heavy alcohol consumption (increases lactic acidosis risk) - Expecting dramatic visible results - metformin's longevity effects are subtle and long-term
Safety Considerations and Contraindications: Metformin is remarkably safe for most, but specific medical conditions, particularly kidney dysfunction, make it dangerous or ineffective. Strict adherence to safety guidelines and transparency with your entire medical team are paramount for minimizing risk. - Not suitable for those with kidney disease (eGFR below 30 is an absolute contraindication; 30-45 requires dose reduction and close monitoring) - Avoid excessive alcohol consumption while on metformin (lactic acidosis risk increases significantly) - Temporarily discontinue before surgeries or procedures involving contrast dye (resume 48 hours after if kidney function is normal) - Liver disease (severe): Use with caution; monitor liver enzymes - Lactic acidosis is extremely rare (<1 in 30,000) but medical emergency - seek immediate care for unusual muscle pain with nausea and difficulty breathing - Pregnancy: Discontinue; discuss with OB/GYN (metformin is sometimes used in gestational diabetes, but this requires specialist guidance) - Drug interactions: Check with pharmacist; metformin can interact with certain diuretics, corticosteroids, and contrast agents
Supports
Gandini S, Puntoni M, Heckman-Stoddard BM, et al.
Metformin use associated with reduced cancer incidence and mortality in diabetic patients.
View paperSupports
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA
Rationale for TAME trial: observational data suggests metformin users may have extended healthspan.
View paperSupports
Campbell JM et al.
Diabetics on metformin had 28% lower mortality than those on other diabetes drugs.
View paper